Public Employees Retirement System of Ohio cut its position in ICU Medical, Inc. (NASDAQ:ICUI – Free Report) by 30.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,546 shares of the medical instruments supplier’s stock after selling 2,934 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in ICU Medical were worth $845,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently bought and sold shares of the company. Hilton Head Capital Partners LLC purchased a new position in ICU Medical in the 4th quarter worth approximately $32,000. Covestor Ltd increased its holdings in shares of ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 126 shares during the period. Strs Ohio lifted its stake in shares of ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after acquiring an additional 300 shares during the last quarter. Rockefeller Capital Management L.P. lifted its stake in shares of ICU Medical by 21.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 146 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in ICU Medical during the 4th quarter valued at about $120,000. 96.10% of the stock is owned by institutional investors.
Insider Buying and Selling
In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the sale, the vice president directly owned 19,460 shares of the company’s stock, valued at approximately $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the sale, the director directly owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.10% of the company’s stock.
ICU Medical Stock Up 2.6%
ICU Medical (NASDAQ:ICUI – Get Free Report) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.19. The business had revenue of $525.77 million for the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business’s revenue for the quarter was down 12.3% on a year-over-year basis. During the same period last year, the firm posted $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, sell-side analysts predict that ICU Medical, Inc. will post 6.51 EPS for the current year.
Wall Street Analyst Weigh In
ICUI has been the topic of several recent research reports. Sanford C. Bernstein lowered ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Needham & Company LLC upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a report on Wednesday, May 27th. KeyCorp lifted their target price on shares of ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 21st. Finally, Zacks Research cut shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $172.00.
Read Our Latest Stock Analysis on ICU Medical
ICU Medical Company Profile
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Featured Articles
- Five stocks we like better than ICU Medical
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.
